Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Classics scholar to close Vergil Week with keynote address April 25
- Psychiatry’s Sara West examines the motives of filicide
- Dental school’s Bruce Latimer discusses the consequences of bipedalism
- Spoken English Language Partners to hold end-of-year study break April 25
- Case Kismat dance team to sell noodles, chai tea as part of fundraiser April 23-24